Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has been given an average rating of “Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $30.71.
ADMS has been the topic of several recent research reports. HC Wainwright set a $45.00 target price on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 17th. Cowen set a $30.00 target price on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. Leerink Swann initiated coverage on shares of Adamas Pharmaceuticals in a research report on Monday, November 12th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, ValuEngine downgraded shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 2nd.
In other news, CEO Gregory T. Went purchased 3,850 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were purchased at an average price of $12.98 per share, for a total transaction of $49,973.00. Following the transaction, the chief executive officer now owns 182,610 shares of the company’s stock, valued at $2,370,277.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 24.60% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. acquired a new position in shares of Adamas Pharmaceuticals during the 3rd quarter valued at $104,000. Metropolitan Life Insurance Co. NY lifted its position in shares of Adamas Pharmaceuticals by 43.2% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 2,293 shares during the period. State Board of Administration of Florida Retirement System acquired a new position in shares of Adamas Pharmaceuticals during the 2nd quarter valued at $203,000. Tower Research Capital LLC TRC acquired a new position in shares of Adamas Pharmaceuticals during the 3rd quarter valued at $162,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Adamas Pharmaceuticals during the 2nd quarter valued at $212,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.
Shares of Adamas Pharmaceuticals stock traded down $0.10 during midday trading on Friday, hitting $9.22. 493,222 shares of the company traded hands, compared to its average volume of 505,903. The firm has a market capitalization of $256.13 million, a PE ratio of -2.32 and a beta of 1.48. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01. Adamas Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $44.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.12. The company had revenue of $10.61 million for the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative net margin of 617.27% and a negative return on equity of 106.74%. As a group, research analysts anticipate that Adamas Pharmaceuticals will post -5.22 earnings per share for the current year.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Further Reading: What is Considered a Good Return on Equity (ROE)?
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.